Skip to main content
Uncategorized

Advancell recovers the rights to Acadra, a treatment for chronic lymphatic B cell leukaemia

By 9 de November de 2009November 18th, 2020No Comments
< Back to news
 09.11.2009

Advancell recovers the rights to Acadra, a treatment for chronic lymphatic B cell leukaemia

Bio-tech firm Advancell, leader in nano-medicine research and cellular methods for in-vitro research, deals with unresolved needs in health and wellbeing through its products and services. The firm has recovered the exclusive rights for the development of Acadra, a treatment which Advancell will continue to develop alone.

This follows an agreement reached with the pharmaceutical company BTG after its recent takeover of Protherics. Advancell had shared product development with Protherics under a licence and joint development agreement signed in 2006.

The new business strategy of BTG, which consists of concentrating activities in the development of pharmaceuticals in advanced clinical trial phases close to registration and their subsequent commercialisation, has created an opportunity for Advancell to recover the rights to Acadra. Sole development of Acadra is an excellent business opportunity as the treatment has already proven its efficiency through in-vitro testing and is demonstrating positive results in ongoing patient tests. Additionally, the market this treatment is aimed at is worth around 250m euros in annual sales. In exchange for recovery of the rights, Advancell will make milestone and royalty payments to BTG, based on future sales of Acadra.